[go: up one dir, main page]

MX2017009699A - Composicion de suspension oftalmica. - Google Patents

Composicion de suspension oftalmica.

Info

Publication number
MX2017009699A
MX2017009699A MX2017009699A MX2017009699A MX2017009699A MX 2017009699 A MX2017009699 A MX 2017009699A MX 2017009699 A MX2017009699 A MX 2017009699A MX 2017009699 A MX2017009699 A MX 2017009699A MX 2017009699 A MX2017009699 A MX 2017009699A
Authority
MX
Mexico
Prior art keywords
ophthalmic
suspension composition
ophthalmic suspension
suspension
treat
Prior art date
Application number
MX2017009699A
Other languages
English (en)
Other versions
MX390671B (es
Inventor
phillips Eric
J Coffey Martin
Shawer Mohannad
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55359733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017009699(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of MX2017009699A publication Critical patent/MX2017009699A/es
Publication of MX390671B publication Critical patent/MX390671B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una suspensión incluye un ingrediente activo oftálmico suspendido en un vehículo de formulación que incluye un agente de suspensión y un derivado de celulosa no iónico. El agente activo oftálmico está presente como partículas que tienen Dv90 <5 µm y Dv50 <1 µm. La suspensión se puede administrar a un paciente para tratar una afección inflamatoria oftálmica.
MX2017009699A 2015-01-26 2016-01-26 Composicion de suspension oftalmica. MX390671B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562107696P 2015-01-26 2015-01-26
PCT/US2016/014872 WO2016123079A1 (en) 2015-01-26 2016-01-26 Ophthalmic suspension composition

Publications (2)

Publication Number Publication Date
MX2017009699A true MX2017009699A (es) 2017-10-23
MX390671B MX390671B (es) 2025-03-21

Family

ID=55359733

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009699A MX390671B (es) 2015-01-26 2016-01-26 Composicion de suspension oftalmica.

Country Status (15)

Country Link
US (3) US10596107B2 (es)
EP (5) EP3250185B1 (es)
JP (1) JP2018507252A (es)
KR (1) KR102538370B1 (es)
CN (1) CN107427464B (es)
AU (4) AU2016211745A1 (es)
BR (1) BR112017016016B1 (es)
CA (1) CA2975106A1 (es)
ES (5) ES3031414T3 (es)
HU (5) HUE048564T2 (es)
MX (1) MX390671B (es)
PL (5) PL3721868T5 (es)
PT (3) PT4082531T (es)
SI (1) SI4268850T1 (es)
WO (1) WO2016123079A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4082531T (pt) 2015-01-26 2023-12-14 Bausch & Lomb Composição de suspensão oftálmica
CA3001957C (en) 2015-10-16 2023-11-14 Sun Pharma Advanced Research Company Limited Ophthalmic solution of difluprednate
ES2972417T3 (es) 2016-05-18 2024-06-12 Sonikure Holdings Ltd Sistema de administración transescleral de fármacos mejorada por ultrasonidos
EP3668505A4 (en) 2017-08-15 2021-05-12 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
EP3853317A4 (en) * 2018-09-21 2022-06-22 PS Therapy Ltd. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
EP4431497A1 (en) * 2019-02-15 2024-09-18 Bausch + Lomb Ireland Limited Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
JP7796305B2 (ja) * 2019-08-18 2026-01-09 アイビュー セラピューティクス，インコーポレイテッド ジフルプレドナートを含むインサイチュゲル形成性眼科用製剤
KR102271247B1 (ko) * 2020-11-04 2021-06-30 삼천당제약주식회사 안과용 현탁액 조성물의 제조방법
CN115887372A (zh) * 2022-10-25 2023-04-04 苏州欧康维视生物科技有限公司 丙酸氟替卡松混悬液及其制备方法
CN115554238A (zh) * 2022-10-25 2023-01-03 苏州欧康维视生物科技有限公司 眼用混悬液及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4540930A (en) 1983-09-12 1985-09-10 Wisconsin Alumni Research Foundation Plywheel-powered mobile X-ray apparatus
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IE63392B1 (en) 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
US5124154A (en) 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
CA2134376C (en) 1993-12-20 2001-10-23 Haresh G. Bhagat Combinations of polymers for use in physiological tear compositions
US5556848A (en) * 1993-12-27 1996-09-17 Senju Pharmaceutical Co., Ltd. Ophthalmic suspension containing diflupredonate
GB9718568D0 (en) * 1997-09-03 1997-11-05 Chauvin Pharmaceuticals Limite Compositions
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
KR20110134525A (ko) 2003-06-13 2011-12-14 알콘, 인코퍼레이티드 시너지성의 2개의 폴리머 배합물을 포함하는 안과용 조성물
US20050197303A1 (en) 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US7919483B2 (en) 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20100234336A1 (en) 2005-11-14 2010-09-16 Erning Xia Ophthalmic Compositions
WO2007058935A2 (en) 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US20120028947A1 (en) 2005-11-14 2012-02-02 Erning Xia Ophthalmic Compositions
US8846770B2 (en) * 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
CN101966143A (zh) 2009-07-28 2011-02-09 胡容峰 加替沙星温度及pH敏感眼用凝胶的制备与应用
SI2965749T1 (sl) 2009-12-03 2018-09-28 Novartis Ag Suspenzije nanodelcev, ki vsebujejo karboksivinilni polimer
KR20140069210A (ko) 2011-09-22 2014-06-09 보오슈 앤드 롬 인코포레이팃드 안과적 겔 조성물
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
WO2013169647A1 (en) 2012-05-08 2013-11-14 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US8765725B2 (en) * 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
MX341663B (es) * 2012-05-11 2016-08-30 Activus Pharma Co Ltd Nanopolvo de compuesto organico, metodo para producirlo y su suspension.
EP2890363A1 (en) 2012-08-31 2015-07-08 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
US20150190407A1 (en) 2014-01-07 2015-07-09 Insite Vision Incorporated Methods for treatment of postoperative inflammation with reduced intraocular pressure
JP6373995B2 (ja) 2014-07-11 2018-08-15 富士フイルム株式会社 眼科用水性組成物
NZ728136A (en) 2014-07-11 2017-10-27 Fujifilm Corp Method for producing aqueous ophthalmic composition, and aqueous ophthalmic composition
US10172852B2 (en) 2014-07-28 2019-01-08 Sun Pharma Advanced Research Company Ltd. Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
PT4082531T (pt) 2015-01-26 2023-12-14 Bausch & Lomb Composição de suspensão oftálmica

Also Published As

Publication number Publication date
PT3721868T (pt) 2022-08-12
BR112017016016A2 (pt) 2018-03-20
MX390671B (es) 2025-03-21
SI4268850T1 (sl) 2025-07-31
ES2787039T3 (es) 2020-10-14
ES2704125T3 (es) 2019-03-14
EP4268850A1 (en) 2023-11-01
AU2023248145B2 (en) 2025-08-28
AU2016211745A1 (en) 2017-08-31
ES2924645T3 (es) 2022-10-10
PL3250185T3 (pl) 2019-05-31
EP3721868B2 (en) 2025-09-03
CN107427464B (zh) 2022-04-05
PL3470059T3 (pl) 2020-11-30
ES2966595T3 (es) 2024-04-23
US10596107B2 (en) 2020-03-24
WO2016123079A1 (en) 2016-08-04
EP3250185B1 (en) 2018-12-05
HUE059639T2 (hu) 2022-12-28
US11534395B2 (en) 2022-12-27
JP2018507252A (ja) 2018-03-15
HUE066045T2 (hu) 2024-07-28
EP4082531A1 (en) 2022-11-02
EP4268850B1 (en) 2025-04-16
EP3470059A1 (en) 2019-04-17
PT4082531T (pt) 2023-12-14
AU2021203027B2 (en) 2023-07-13
PL3721868T3 (pl) 2022-11-07
EP3250185A1 (en) 2017-12-06
HUE041945T2 (hu) 2019-06-28
ES3031414T3 (en) 2025-07-08
PL4268850T3 (pl) 2025-08-04
US20160213609A1 (en) 2016-07-28
KR20170105610A (ko) 2017-09-19
AU2025271194A1 (en) 2025-12-18
HUE071679T2 (hu) 2025-09-28
US20230140895A1 (en) 2023-05-11
PL3721868T5 (pl) 2025-12-22
EP4082531B1 (en) 2023-10-11
EP3470059B1 (en) 2020-04-01
PT4268850T (pt) 2025-06-04
ES2924645T5 (en) 2025-12-15
EP3721868B1 (en) 2022-06-01
EP3721868A1 (en) 2020-10-14
CN107427464A (zh) 2017-12-01
PL4082531T3 (pl) 2024-04-08
AU2023248145A1 (en) 2023-11-02
CA2975106A1 (en) 2016-08-04
BR112017016016B1 (pt) 2023-12-19
US20200214977A1 (en) 2020-07-09
AU2021203027A1 (en) 2021-06-10
KR102538370B1 (ko) 2023-06-01
HUE048564T2 (hu) 2020-08-28

Similar Documents

Publication Publication Date Title
MX2017009699A (es) Composicion de suspension oftalmica.
CL2019003432A1 (es) Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de ciclooxigenasa (cox) o un fármaco antiinflamatorio no esterioidal (aine), y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014).
MX384021B (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
BR112014014832A8 (pt) formulação e método de controlar fungos
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
CR20170393A (es) Encapsulado de agentes activos de alta potencia
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
MX2018000285A (es) Composicion para desobstruir la nariz congestionada que tiene actividad antiviral.
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
BR112015011743A2 (pt) conservantes
CL2017000120A1 (es) Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares
SV2017005603A (es) Formulacion solida oral que contiene irinotecan y metodo de preparacion de la misma
MX2016005764A (es) Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos.
BR112016017897A8 (pt) uso de composto de carboxamida heterocíclica de diamino no tratamento de câncer relacionado ao axl, composição farmacêutica e combinação
CL2015002817A1 (es) Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).
MX366277B (es) Composiciones de agente activo retinoide particuladas, secas y finas y formulaciones topicas que incluyen las mismas.
CL2012001835A1 (es) Uso de una formulacion que comprende un agente viscogenico y moxifloxacina para preparar un medicamento util para tratar el oido medio.
CL2015001748A1 (es) Formulaciones antiparasitarias transdermicas
MX2018000021A (es) Composiciones multifasicas.
NZ767710A (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
MX2016014256A (es) Formulaciones y metodos para el suministro vaginal de antiprogestinas.
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol